Your selfies may help detect pancreatic cancer

Image
Press Trust of India Washington
Last Updated : Aug 29 2017 | 1:28 PM IST
Scientists have developed an app that allows people to easily screen for pancreatic cancer and other diseases by just clicking a selfie.
One of the earliest symptoms of pancreatic cancer, as well as other diseases, is jaundice, a yellow discolouration of the skin and eyes caused by a buildup of bilirubin in the blood, researchers said.
The ability to detect signs of jaundice when bilirubin levels are minimally elevated - but before they are visible to the naked eye - could enable an entirely new screening programme for individuals at risk, they said.
The BiliScreen app, developed by researchers at the University of Washington in the US, uses a smartphone camera, computer vision algorithms and machine learning tools to detect increased bilirubin levels in a person's sclera, or the white part of the eye.
The team developed a computer vision system to automatically and effectively isolate the white parts of the eye, which is a valuable tool for medical diagnostics.
The app then calculates the colour information from the sclera-based on the wavelengths of light that are being reflected and absorbed-and correlates it with bilirubin levels using machine learning algorithms.
To account for different lighting conditions, the team tested BiliScreen with two different accessories: paper glasses printed with coloured squares to help calibrate colour and a three dimensional (3D) printed box that blocks out ambient lighting.
"Pancreatic cancer is a terrible disease with no effective screening right now," said Jim Taylor, professor at University of Washington.
"Our goal is to have more people who are unfortunate enough to get pancreatic cancer to be fortunate enough to catch it in time to have surgery that gives them a better chance of survival," Taylor added.
In an initial clinical study of 70 people, the BiliScreen app-used in conjunction with a 3D printed box that controls the eye's exposure to light-correctly identified cases of concern 89.7 per cent of the time, compared to the blood test currently used.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 29 2017 | 1:28 PM IST

Next Story